Implications for sequencing of biologic therapy and choice of second anti-TNF in patients with inflammatory bowel disease: Results from the IMmunogenicity to Second Anti-TNF therapy (IMSAT) therapeutic drug monitoring study
- Chanchlani, N.
- Lin, S.
- Auth, M. K.
- Lee, C. L.
- Robbins, H.
- Looi, S.
- Murugesan, S. V.
- Riley, T.
- Preston, C.
- Stephenson, S.
- Cardozo, W.
- Sonwalkar, S. A.
- Allah-Ditta, M.
- Mansfield, L.
- Durai, D.
- Baker, M.
- London, I.
- London, E.
- Gupta, S.
- Di Mambro, A.
- Murphy, A.
- Gaynor, E.
- Jones, K. D. J.
- Claridge, A.
- Sebastian, S.
- Ramachandran, S.
- Selinger, C. P.
- Borg-Bartolo, S. P.
- Knight, P.
- Sprakes, M. B.
- Burton, J.
- Kane, P.
- Lupton, S.
- Fletcher, A.
- Gaya, D. R.
- Colbert, R.
- Seenan, J. P.
- MacDonald, J.
- Lynch, L.
- McLachlan, I.
- Shields, S.
- Hansen, R.
- Gervais, L.
- Jere, M.
- Akhtar, M.
- Black, K.
- Henderson, P.
- Russell, R. K.
- Lees, C. W.
- Derikx, Laap
- Lockett, M.
- Betteridge, F.
- De Silva, A.
- Hussenbux, A.
- Beckly, J.
- Bendall, O.
- Hart, J. W.
- Thomas, A.
- Hamilton, B.
- Gordon, C.
- Chee, D.
- McDonald, T. J.
- Nice, R.
- Parkinson, M.
- Gardner-Thorpe, H.
- Butterworth, J. R.
- Javed, A.
- Al-Shakhshir, S.
- Yadagiri, R.
- Maher, S.
- Pollok, R. C. G.
- Ng, T.
- Appiahene, P.
- Donovan, F.
- Lok, J.
- Chandy, R.
- Jagdish, R.
- Baig, D.
- Mahmood, Z.
- Marsh, L.
- Moss, A.
- Abdulgader, A.
- Kitchin, A.
- Walker, G. J.
- George, B.
- Lim, Y. H.
- Gulliver, J.
- Bloom, S.
- Theaker, H.
- Carlson, S.
- Cummings, J. R. F.
- Livingstone, R.
- Beale, A.
- Carter, J. O.
- Bell, A.
- Coulter, A.
- Snook, J.
- Stone, H.
- Kennedy, N. A.
- Goodhand, J. R.
- Ahmad, T.
DOIAbstract
BACKGROUND: Anti-drug antibodies are associated with treatment failure to anti-TNF agents in patients with inflammatory bowel disease (IBD). AIM: To assess whether immunogenicity to a patient's first anti-TNF agent would be associated with immunogenicity to their second, irrespective of drug sequence METHODS: We conducted a UK-wide, multicentre, retrospective cohort study to report rates of immunogenicity and treatment failure of second anti-TNF therapies in 1058 patients with IBD who underwent therapeutic drug monitoring for both infliximab and adalimumab. The primary outcome was immunogenicity to the second anti-TNF drug, defined at any timepoint as an anti-TNF antibody concentration ≥9 AU/ml for infliximab and ≥6 AU/ml for adalimumab. RE...
Add to ORKG